Hepatitis B and C virus infection and hepatocellular carcinoma in China: A review of epidemiology and control measures

Journal of Epidemiology

Volumn 21, Issue 6, 2011, Pages 401-416

  Tanaka, Masahiro ^a,b   Katayama, Francisco ^c   Kato, Hideaki ^d   Tanaka, Hideo ^e   Wang, Jianbing ^f   Qiao, You Lin ^f   Inoue, Manami ^g  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f CANCER HOSPITAL   (China)

^g NATIONAL CANCER CENTER   (Japan)

Author keywords

China; Control; Epidemiology; Hepatitis; Hepatocellular carcinoma

Indexed keywords

CHINA; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION CONTROL; LIVER CELL CARCINOMA; LIVER TUMOR; METHODOLOGY; REVIEW;

CARCINOMA, HEPATOCELLULAR; CHINA; HEPATITIS B; HEPATITIS C; HUMANS; INFECTION CONTROL; LIVER NEOPLASMS;

EID: 84862942769     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.JE20100190     Document Type: Review

References (114)

1. Ministry of Health, China. National Plan for Prevention and Treatment against Hepatitis B for 2006-10.
2. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet. 2004;364:417-22.
3. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38 Suppl 3:S158-68.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
5. Qu ZY. An epidemiological study on the distribution of HBsAg and anti-HBs in China. Chin J Microbiol Immunol. 1986; 6:S20-40 (in Chinese).
6. Lu FM, Li T, Liu S, Zhuang H. Epidemiology and prevention of hepatitis B virus infection in China. J Viral Hepat. 2010;17 Suppl:4-9.
7. Hu ZH, Qu ZY, Jing Q. The overall infection rate of HBV in Chinese general population by sampling investigation. Chin J Microbiol Immunol. 1986;6:S70-7.
8. Liu CB, Xu ZY, Cao HL, Sun YD, Cheng DB, Jing Q, et al. Sero-epidemiology of HBV infection in four provinces in China. Chin J Virol. 1991;7:S8-14.
9. Xia GL, Liu CB, Cao HL, Bi SL, Zhan MY, Su CA, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int Hepatol Commun. 1996;5:62-73.
10. Chunming C; Centers for Disease Control (CDC). Diseases surveillance in China. MMWR Morb Mortal Wkly Rep. 1992;41 Suppl:111-22.
11. Mooney P. Counting the dead in China. Bull World Health Organ. 2006;84(3):168-9.
12. Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaka R, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology. 2004;47(1):32-40.
13. National Cancer Center, Korea. Cancer Facts and Figures 2008 in Korea. 2008.
14. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007;42:513-21.
15. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27:6550-7.
16. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis. 2009;200(1):39-47.
17. Dong Y, Liu SL, Zhai XJ, Zhu FC, Pan H, Yu JX, et al. A serological and molecular survey of hepatitis B in children 15 years after inception of the national hepatitis B vaccination program in eastern China. J Med Virol. 2009;81:1517-24.
18. Zhao SM, Li HC, Lou H, Lu XX, Yu XF, Gao DH, et al. High Prevalence of HBV in Tibet, China. Asian Pac J Cancer Prev. 2001;2:299-304.
19. Zhuo J, Tao G, Ebrahim SH, Wang S, Luo Z, Wang H. The relationship of hepatitis B virus infection between adults and their children in Guangxi Province, China. J Hepatol. 2000;33:628-31.
20. Sherlock CH, Zhuo L, Meng XL, Lin XY, Stiver HG. Seroepidemiology of hepatitis C virus in Beijing, China. Clin Diagn Virol. 1993 Mar;1(1):17-22.
21. Ito S, Yao DF, Nii C, Horie T, Kamamura M, Nishikado T, et al. Incidence of hepatitis C virus (HCV) antibodies and HCVRNA in blood donors and patients with liver diseases in the inshore area of the Yangtze River. J Gastroenterol Hepatol. 1994;9:245-9.
22. Wu RR, Mizokami M, Lau JY, Ohno T, Fang ZX, Ohba K, et al. Seroprevalence of hepatitis C virus infection and itsgenotype in Lanzhou, western China. J Med Virol. 1995; 45:174-8.
23. Yuan JM, Govindarajan S, Henderson BE, Yu MC. Low prevalence of hepatitis C infection in hepatocellular carcinoma (HCC) cases and population controls in Guangxi, a hyperendemic region for HCC in the People's Republic of China. Br J Cancer. 1996;74:491-3.
24. Zhang M, Sun XD, Mark SD, Chen W, Wong L, Dawsey SM, et al. Hepatitis C virus infection, Linxian, China. Emerg Infect Dis. 2005;11:17-21.
25. Liu F, Chen K, He Z, Ning T, Pan Y, Cai H, et al. Hepatitis C seroprevalence and associated risk factors, Anyang, China. Emerg Infect Dis. 2009;15:1819-22.
26. IARC. World Cancer Report 2008. Lyon: IARC; 2008. p. 351.
27. Zeng G, Wang Z, Wen S, Jiang J, Wang L, Cheng J, et al. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat. 2005;12:609-17.
28. Zhu CT, Dong CL. Characteristics of general distribution of hepatitis B virus genotypes in China. Hepatobiliary Pancreat Dis Int. 2009;8(4):397-401.
29. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology. 2003;124:925-32.
30. Xi LF, Xu ZY, Sheng YD. The horizontal and perinatal transmission of hepatitis B virus infection. Chin J Virol. 1991;7:s21-4.
31. Yao JL. Perinatal transmission of hepatitis B virus infection and vaccination in China. Gut. 1996;38 Suppl 2:S37-8.
32. Yao GB. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut. 1996;38 Suppl 2:S39-42.
33. Liu LH, Wang HX, Yin DC. Prevalence and incidence of hepatitis B virus infection in 3-5 years old kindergarten children. J Virol. 1991;7:S25-9.
34. Fang XS, Li LC, An K. HBV infection among newly married couples. Chin J Virol. 1991;7:S35-7.
35. Liu J, Fan D. Hepatitis B in China. Lancet. 2007;369:1582-3.
36. Zhang HW, Yin JH, Li YT, Li CZ, Ren H, Gu CY, et al. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut. 2008;57:1713-20.
37. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ. 1999;77:789-800.
38. UNAIDS. 2008 Report on the global AIDS epidemic. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/.
39. Yan YW, Yan J, Zhang GP, Gao ZL, Jian HX. Prevalence of injections and knowledge of safe injections among rural residents in Central China. Singapore Med J. 2007;48:769-74.
40. Yan Y, Zhang G, Chen Y, Zhang A, Guan Y, Ao H. Study on the injection practices of health facilities in Jingzhou district, Hubei, China. Indian J Med Sci. 2006;60:407-16.
41. Calls to improve needle safety surge. China Daily. December 24, 2005. http://www.chinadaily.com.cn/english/doc/2005-12/24/content_506239.htm.
42. Li L, Kobayashi Y, Xu A, Chiba Y, Song L, Xiao Z, et al. [Survey of knowledge, attitude and behavior regarding safe injection among health practitioners in Shandong, China]. Nippon Koshu Eisei Zasshi. 2003;50:515-25 (in Japanese).
43. Li Q, Ou JM, Zeng G. A cross-sectional survey on injection safety in health facilities in Wulong county, Chongqing city. Zhonghua Liu Xing Bing Xue Za Zhi. 2003;24:176-9 (in Chinese).
44. China vows to curb AIDS spread. China Daily , 2005. http://www.chinadaily.com.cn/english/doc/2005-12/01/content_499488.htm (accessed July 24, 2009).
45. Murakami H, Kobayashi M, Zhu X, Li Y, Wakai S, Chiba Y. Risk of transmission of hepatitis B virus through childhood immunization in northwestern China. Soc Sci Med. 2003; 57:1821-32.
46. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol. 2005;34:132-7.
47. Ding J, Akira T, Noriko Y, Mikihiro T, Takayasu D. Study of hepatitis C virus genotype in Guizhou area of southwestern. Chin Med J (Engl). 1998;111(2):128-31.
48. Chen YD, Liu MY, Yu WL, Li JQ, Peng M, Dai Q, et al. Hepatitis C virus infections and genotypes in China. Hepatobiliary Pancreat Dis Int. 2002;1:194-201.
49. Nakano T, Lu L, He Y, Fu Y, Robertson BH, Pybus OG. Population genetic history of hepatitis C virus 1b infection in China. J Gen Virol. 2006;87:73-82.
50. Garten RJ, Lai S, Zhang J, Liu W, Chen J, Vlahov D, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol. 2004; 33:182-8.
51. Bao YP, Liu ZM. Systematic review of HIV and HCV infection among drug users in China. Int J STD AIDS. 2009;20:399-405.
52. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health. 2008;122:990-1003.
53. CHINESE HEALTH STATISTICAL DIGEST 2010. http://www.moh.gov.cn/publicfiles//business/htmlfiles/zwgkzt/ptjty/digest2010/index.html.
54. Yang L, Parkin MD, Ferlay J, Li L, Chen Y. Estimates of Cancer Incidence in China for 2000 and Projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005;14:243-50.
55. IARC Cancer Incidence In Five Continents, 2007.
56. Shanghai Cancer Registry. Cancer incidence, mortality and survival rate in Shanghai, 1973-2000.
57. Jin F, Devesa SS, Zheng W, Blot WJ, Fraumeni JF Jr, Gao YT. Cancer incidence trends in urban Shanghai, 1972-1989. Int J Cancer. 1993;53:764-70.
58. Hao XS, Wang PP, Chen KX, Li Q, He M, Yu SB, et al. Twenty-year trends of primary liver cancer incidence rates in an urban Chinese population. Eur J Cancer Prev. 2003;12:273-9.
59. Law L, Mang O. Cancer incidence in Hong Kong. Hong Kong Med Diary. 2007;12:18-21.
60. Chen JG, Zhu J, Parkin DM, Zhang YH, Lu JH, Zhu YR, et al. Trends in the incidence of cancer in Qidong, China, 1978-2002. Int J Cancer. 2006;119:1447-54.
61. Yeh FS, Mo CC, Luo S, Henderson BE, Tong MJ, Yu MC. A serological case-control study of primary hepatocellular carcinoma in Guangxi, China. Cancer Res. 1985;45:872-3.
62. Cong WM, Wu MC, Zhang XH, Chen H, Yuan JY. Primary hepatocellular carcinoma in women of mainland China. A clinicopathologic analysis of 104 patients. Cancer. 1993; 71:2941-5.
63. Okuno H, Xie ZC, Lu BY, Qin X, Takasu M, Kano H, et al. A low prevalence of anti-hepatitis C virus antibody in patients with hepatocellular carcinoma in Guangxi Province, southern China. Cancer. 1994;73:58-62.
64. Yang BH, Xia JL, Huang LW, Tang ZY, Chen MS, Li JQ, et al. Changed clinical aspects of primary liver cancer in China during the past 30 years. Hepatobiliary Pancreat Dis Int. 2004;3:194-8.
65. Gao JD, Shao YF, Xu Y, Ming LH, Wu ZY, Liu GT, et al. Tight association of hepatocellular carcinoma with HBV infection in North China. Hepatobiliary Pancreat Dis Int. 2005;4:46-9.
66. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev. 1994;3:3-10.
67. Zhang JY, Dai M, Wang X, Lu WQ, Li DS, Zhang MX, et al. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China. Int J Epidemiol. 1998;27:574-8.
68. Yu SZ, Huang XE, Koide T, Cheng G, Chen GC, Harada K, et al. Hepatitis B and C viruses infection, lifestyle and genetic polymorphisms as risk factors for hepatocellular carcinoma in Haimen, China. Jpn J Cancer Res. 2002;93:1287-92.
69. Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight year follow up of the 90000 preson Haimen City cohort: Hepatocellular carcinoma mortality, risk factors and gender differences. Cancer Epidemiol Biomarkers Prev. 2002;11: 369-76.
70. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer. 2005;92:607-12.
71. World Cancer Research Fund/American Institute of Cancer Research. Alcoholic drinks, Food, Nutrition, Physical activity, and the Prevention of Cancer: A Global perspective. Washington DC: AICR; 2007. p. 277-288.
72. Zhang JY, Wang X, Han SG, Zhuang H. A case-control study of risk factors for hepatocellular carcinoma in Henan, China. Am J Trop Med Hyg. 1998;59:947-51.
73. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology. 1999;30:379-83.
74. Liu BQ, Peto R, Chen ZM, Boreham J, Wu YP, Li JY, et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ. 1998 Nov 21;317:1411-22.
75. Yuan JM, Ross RK, Wang XL, Gao YT, Henderson BE, Yu MC. Morbidity and mortality in relation to cigarette smoking in Shanghai, China. A prospective male cohort study. JAMA. 1996;275(21):1646-50.
76. Chen ZM, Liu BQ, Boreham J, Wu YP, Chen JS, Peto R. Smoking and liver cancer in China: case-control comparison of 36,000 liver cancer deaths vs. 17,000 cirrhosis deaths. Int J Cancer. 2003;107:106-12.
77. Wang JB, Jiang Y, Wei WQ, Yang GH, Qiao YL, Boffetta P. Estimation of cancer incidence and mortality attributable to smoking in China. Cancer Causes Control. 2010;21:959-65.
78. International Agency for Research on cancer. Some naturally occurring substances: Food items and constituents, heterocyclic aromatic amines and mycotoxins. IARC Monogr Eval Carcinog Risk Humans. Vol. 56. Lyon, IACR, 1993.
79. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004;127 Suppl 1:S72-8.
80. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in Southern Guangxi, China. Cancer Res. 1989;49:2506-9.
81. Campbell TC, Chen JS, Liu CB, Li JY, Parpia B. Nonassociation of aflatoxin with primary liver cancer in a crosssectional ecological survey in the People's Republic of China. Cancer Res. 1990;50:6882-93.
82. Hsing AW, Guo W, Chen J, Li JY, Stone BJ, Blot WJ, et al. Correlates of liver cancer mortality in China. Int J Epidemiol. 1991;20:54-9.
83. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology. 2002;36:1214-20.
84. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst. 2000;92:1159-64.
85. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:S294-308.
86. Gao Y, Jiang Q, Zhou X, Ding B, Wang R, Zhao G, et al. HBV infection and familial aggregation of liver cancer: an analysis of case-control family study. Cancer Causes Control. 2004; 15:845-50.
87. Luo RH, Zhao ZX, Zhou XY, Gao ZL, Yao JL. Risk factors for primary liver carcinoma in Chinese population. World J Gastroenterol. 2005 Jul 28;11:4431-4.
88. Qiu DC, Hubbard AE, Zhong B, Zhang Y, Spear RC. A matched, case-control study of the association between Schistosoma japonicum and liver and colon cancers, in rural China. Ann Trop Med Parasitol. 2005;99:47-52.
89. Ohmae H. Liver fluke and Schistosomiasis. GI Research. 2006;14:34-40 (in Japnese).
90. Wang N, Zheng Y, Yu X, Lin W, Chen Y, Jiang Q. Sexmodified effect of hepatitis B virus infection on mortality from primary liver cancer. Am J Epidemiol. 2009;169:990-5.
91. Zhou YH, Wu C, Zhuang H. Vaccination against hepatitis B: the Chinese experience. Chin Med J (Engl). 2009;122:98-102.
92. Ministry of Health, China. Immunization Strategy of Hepatitis B Vaccine in China. 2002.
93. WHO. Expanded Programme on Immunisation. http://www.who.int/countries/eth/areas/immunization/en/.
94. WHO. Factsheet No. 204. 2008. http://www.who.int/mediacentre/factsheets/fs204/en/.
95. China vows to curb AIDS spread. China Daily Dec 1, 2005.
96. Shan H, Wang JX, Ren FR, Zhang YZ, Zhao HY, Gao GJ, et al. Blood banking in China. Lancet. 2002;360:1770-5.
97. Yin G, Kawahara K. Progress in blood banking in China and problems in achieving a volunteer-based blood donation system. Jpn J Transfusion Med. 2003;49:568-71.
98. Yu X, Huang Y, Qu G, Xu J, Hui S. Safety and current status of blood transfusion in China. Lancet. 2010;375:1420-1.
99. The central people's governments of the People's Republic of China. The Blood Donation Law of People's Republic of China. Oct 1, 1998. http://www.gov.cn/banshi/2005-08/01/content_18963.htm (in Chinese).
100. Volunteer blood donation rate hits over 90% in Shanghai. People's Daily Online (Japanese version). Nov. 7, 2008.
101. Liwei Q, Kawahara K. Compensation system for patients infected following blood transfusion in Shanghai, China and Japan. Jpn J Transfusion Cell Ther. 2006;52:512-6.
102. Beasley RP, Lin CC, Chien CS, Chen CJ, Hwang LY. Geographic distribution of HBsAg carriers in China. Hepatology. 1982;2:553-6.
103. WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec. 1997;72:341-8.
104. Tanaka K, Hirohata T, Takeshia S. Blood transfusion, alcohol consumption, and cigarette smoking in causation of hepatocellular carcinoma: a case-control study in Fukuoka, Japan. Jpn J Cancer Res. 1988;79:1075-82.
105. Tanaka K, Hirohata T, Takeshita S, Hirohata I, Koga S, Sugimachi K, et al. Hepatitis. B virus, cigarette smoking and alcohol consumption in the development of hepatocellular cancer: a case control study in Fukuoka, Japan. Int J Cancer. 1992;51:509-14.
106. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797-801.
107. Pyong SJ, Tsukuma H, Hiyama T. Case-control study of hepatocellular carcinoma among Koreans living in Osaka, Japan. Jpn J Cancer Res. 1994;85:674-9.
108. Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, et al. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2008;17:846-54.
109. Sharp GB, Lagarde F, Mizuno T, Sauvaget C, Fukuhara T, Allen N, et al. Relationship of hepatocellular carcinoma to soya food consumption: a cohort-based, case-control study in Japan. Int J Cancer. 2005;115:290-5.
110. Koide T, Ohno T, Huang XE, Iijima Y, Sugihara K, Mizokami M, et al. HBV/HCV Infection, Alcohol, Tobacco and Genetic Polymorphisms for Hepatocellular Carcinoma in Nagoya, Japan. Asian Pac J Cancer Prev. 2000;1:237-43.
111. Shibata A, Fukuda K, Nishiyori A, Ogimoto I, Sakata R, Tanikawa K. A case-control study on male hepatocellular carcinoma based on hospital and community controls. J Epidemiol. 1998;8:1-5.
112. WHO. Global status repot on alcohol. Geneva: WHO; 2004.
113. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol. 1988;69(Pt 10):2575-83.
114. Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology. 2003;46:329-38.